Molecular Target Synopsis
Overview
Domains and Structures
Drugs and Clinical Candidates
Druggability
Chemistry
Ligand Efficiency Plot
Pathways
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
RNAi
Mutations
Germline Genetics

ACP4 (Q9BZG2) - Overview - Molecular Target Synopsis

Protein


ACP4, Testicular acid phosphatase
Enzyme Classification 3.1.3.2
UniProt Q9BZG2

Also Known as PPAT_HUMAN, ACP4, ACPT

May dephosphorylate receptor tyrosine-protein kinase ERBB4 and inhibits its ligand-induced proteolytic cleavage (PubMed:15219672). May play a role in odontogenesis (PubMed:27843125). Homodimer.

Isoforms / Transcripts (Protein Coding)


Protein Length Ensembl Gene Ensembl Transcript Ensembl Protein Uniprot Isoform
426ENSG00000142513ENST00000270593ENSP00000270593Q9BZG2-1
333ENSG00000142513ENST00000270594ENSP00000270594Q9BZG2-2
92Q9BZG2-3

Sub-cellular localization


UniProt: ACP4 is active in the following subcellular-locations: membrane.
GO terms: ACP4 is active in the following subcellular-locations: integral component of membrane, postsynaptic membrane.



UniProt
GO terms

Gene Copy Number Variation


In COSMIC - Cell Lines Project ACP4 has gain in 2 cell-lines, loss in 1 cell-lines and no signal in 1002 cell-lines. (see details)

Gene Expression


In NCI60, the highest expressing cell lines are:

In Array Express (RNA-seq of 675 commonly used human cancer cell lines), the highest expressing cell lines are:

In Array Express (RNA-seq of long poly adenylated RNA and long non poly adenylated RNA from ENCODE cell lines), the highest expressing cell lines are:

(see details)

3D Structures


At greater than 35% identity similarity to ACP4 there are:
6 structures (18 chains) solved
6 are solved in complex with at least one small molecule ligand
1 are solved with an approved drug

ACP4 is solved in complex with the approved drug(s):

TAR/TARTARIC ACID (1RPA_A).

(see details)
Molecular Target 3D Synopsis

Screening and Chemistry


ACP4 has been screened with compounds ( bioactivities). (see details)